抗体–药物偶联物在HER2阳性乳腺癌治疗中的研究进展
Research Progress of Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
DOI: 10.12677/ACM.2024.141256, PDF,   
作者: 古丽斯热·阿不都克里木, 赵 兵*：新疆医科大学附属肿瘤医院，新疆 乌鲁木齐
关键词: 乳腺癌；HER2阳性；抗体–药物偶联物；Breast Cancer； HER2-Positive； Antibody-Drug Conjugate
摘要: 乳腺癌已成为女性中最常见的癌症，也是全球女性癌症性相关死亡的第二大病因。HER2阳性乳腺癌的主要特征是HER2过表达，也被认为是第二具侵袭性的亚型。为了获得最大的抗肿瘤活性，使更多的HER2乳腺癌患者受益，研究者们将抗体和细胞毒性药物结合在一起形成抗体–药物偶联物。抗体–药物偶联物(ADC)正在彻底改变癌症治疗，增加了另一种重要的系统治疗新类别。ADC是一种特殊设计的治疗方法，它通过定向的抗体药物传递和释放细胞毒性化疗有效载荷来靶向表达特定癌症抗原的细胞。本文将重点介绍几种用于乳腺癌治疗的ADC的研究进展，并讨论它们所带来的机遇和挑战。
Abstract: Breast cancer has become the most common cancer among women and the second leading cause of cancer-related deaths among women worldwide. HER2-positive breast cancer is characterized pri-marily by HER2 overexpression, which is also considered to be the second most aggressive subtype. To achieve maximum antitumor activity and benefit more HER2 breast cancer patients, the re-searchers combined the antibody with the cytotoxic drug to form an antibody-drug conjugate. An-tibody-drug conjugate (ADC) are revolutionizing cancer therapy, adding another important new class of systemic therapies. ADC is a specially designed therapy that targets cells expressing specific cancer antigens through targeted antibody drug delivery and the release of cytotoxic chemotherapy payloads. This article will highlight the research advances in several ADCs for the treatment of breast cancer and discuss the opportunities and challenges they present.
文章引用：古丽斯热·阿不都克里木, 赵兵. 抗体–药物偶联物在HER2阳性乳腺癌治疗中的研究进展[J]. 临床医学进展, 2024, 14(1): 1801-1807. https://doi.org/10.12677/ACM.2024.141256

参考文献

[1] Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. [Google Scholar] [CrossRef] [PubMed]
[2] Perou, C.M., Sorlie, T., Eisen, M.B., et al. (2000) Molecular Por-traits of Human Breast Tumours. Nature, 406, 747-752. [Google Scholar] [CrossRef] [PubMed]
[3] Johnson, K.S., Conant, E.F. and Soo, M.S. (2021) Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Journal of Breast Imaging, 3, 12-24. [Google Scholar] [CrossRef] [PubMed]
[4] Wolff, A.C., Hammond, M.E.H., Allison, K.H., et al. (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 36, 2105-2122.
[5] Al-thoubaity, F.K. (2020) Molecular Classification of Breast Cancer: A Retrospective Cohort Study. Annals of Medicine and Surgery, 49, 44-48. [Google Scholar] [CrossRef] [PubMed]
[6] 金振硕, 王海燕. 通过JAK通路促进乳腺癌的免疫治疗[J]. 中国免疫学杂志, 2019, 35(23): 2942-2945.
[7] Ravdin, P.M. and Chamness, G.C. (1995) The c-erbB-2 Proto-Oncogene as a Prognostic and Predictive Marker in Breast Cancer: A Para-digm for the Development of Other Macromolecular Markers—A Review. Gene, 159, 19-27. [Google Scholar] [CrossRef] 
[8] Bredin, P., Walshe, J.M. and Denduluri, N. (2020) Systemic Therapy for Metastatic HER2-Positive Breast Cancer. Seminars in Oncology, 47, 259-269. [Google Scholar] [CrossRef] [PubMed]
[9] Zhang, L., Li, Z.J., Zhang, J., et al. (2020) De Novo Meta-static Breast Cancer: Subgroup Analysis of Molecular Subtypes and Prognosis. Oncology Letters, 19, 2884-2894. [Google Scholar] [CrossRef] [PubMed]
[10] Moasser, M.M. (2007) The Oncogene HER2: Its Signaling and Trans-forming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. [Google Scholar] [CrossRef] [PubMed]
[11] Singh, H., Walker, A.J., Amiri-Kordestani, L., et al. (2018) US Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. Clinical Cancer Research, 24, 3486-3491. [Google Scholar] [CrossRef] 
[12] Howie, L.J., Scher, N.S., Amiri-Kordestani, L., et al. (2019) FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer. Clinical Cancer Research, 25, 2949-2955. [Google Scholar] [CrossRef] 
[13] Saura, C., Oliveira, M., Feng, Y.H., et al. (2020) Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated with ≥2 HER2-Directed Regimens: Phase III NALA Trial. Journal of Clinical Oncology, 38, 3138-3149. [Google Scholar] [CrossRef] 
[14] Chumsri, S., Li, Z., Serie, D.J., et al. (2019) Incidence of Late Relapses in Patients with HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. Journal of Clinical Oncology, 37, 3425-3435. [Google Scholar] [CrossRef] 
[15] Drago, J.Z., Modi, S. and Chandarlapaty, S. (2021) Unlocking the Po-tential of Antibody-Drug Conjugates for Cancer Therapy. Nature Reviews Clinical Oncology, 18, 327-344. [Google Scholar] [CrossRef] [PubMed]
[16] Nagayama, A., Ellisen, L.W., Chabner, B., et al. (2017) Anti-body-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Targeted On-cology, 12, 719-739. [Google Scholar] [CrossRef] [PubMed]
[17] Jain, N., Smith, S.W., Ghone, S., et al. (2015) Current ADC Linker Chemistry. Pharmaceutical Research, 32, 3526-3540. [Google Scholar] [CrossRef] [PubMed]
[18] Beck, A., Goetsch, L., Dumontet, C., et al. (2017) Strategies and Challenges for the Next Generation of Antibody Drug Conjugates. Nature Reviews Drug Discovery, 16, 315-337. [Google Scholar] [CrossRef] [PubMed]
[19] Norsworthy, K.J., Ko, C.W., Lee, J.E., et al. (2018) FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. Oncologist, 23, 1103-1108. [Google Scholar] [CrossRef] [PubMed]
[20] Modi, S., Jacot, W., Yamashita, T., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 387, 9-20. [Google Scholar] [CrossRef] 
[21] Hafeez, U., Parakh, S., Gan, H.K., et al. (2020) Antibody-Drug Conjugates for Cancer Therapy. Molecules, 25, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[22] Burris, H.A., Rugo, H.S., Vukelja, S.J., et al. (2011) Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Re-ceptor 2 (HER2)-Positive Breast Cancer after Prior HER2-Directed Therapy. Journal of Clinical Oncology, 29, 398-405. [Google Scholar] [CrossRef] 
[23] Krop, I.E., Kim, S.B., Martin, A.G., et al. (2017) Trastuzumab Emtansine versus Treatment of Physician’s Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial. The Lancet Oncolo-gy, 18, 743-754. [Google Scholar] [CrossRef] 
[24] Cardoso, F., Paluch-Shimon, S., Senkus, E., et al. (2020) 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Annals of Oncology, 31, 1623-1649. [Google Scholar] [CrossRef] [PubMed]
[25] Von Minckwitz, G., Huang, C.S., Mano, M.S., et al. (2019) Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medi-cine, 380, 617-628. [Google Scholar] [CrossRef] 
[26] Modi, S., Saura, C., Yamashita, T., et al. (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. New England Journal of Medicine, 382, 610-621. [Google Scholar] [CrossRef] 
[27] Hurvitz, S.A., Hegg, R., Chung, W.P., et al. (2023) Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: Up-dated Results from DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial. The Lancet, 401, 105-117. [Google Scholar] [CrossRef] 
[28] Diéras, V., Deluche, E., Lusque, A., et al. (2022) Trastuzumab Deruxtecan (T-DXd) for Advanced Breast Cancer Patients (ABC), Regardless HER2 Status: A Phase II Study with Biomarkers Analysis (DAISY). Cancer Research, 82, PD8-02. [Google Scholar] [CrossRef] 
[29] Powell, C.A., Modi, S., Iwata, H., et al. (2022) Pooled Analysis of Drug-Related Interstitial Lung Disease and/or Pneumonitis in Nine Trastuzumab Deruxtecan Monotherapy Studies. ESMO Open, 7, Article ID: 100554. [Google Scholar] [CrossRef] [PubMed]
[30] Banerji, U., van Herpen, C.M.L., Saura, C., et al. (2019) Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study. The Lancet Oncology, 20, 1124-1135. [Google Scholar] [CrossRef] 
[31] Manich, C.S., O’Shaughnessy, J., Aftimos, P.G., et al. (2021) Primary Outcome of the Phase III SYD985.002/TULIP Trial Comparing Vic-Trastuzumab Duocarmazine to Physician’s Choice Treatment in Patients with Pre-Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer. Annals of Oncology, 32, S1288. [Google Scholar] [CrossRef] 
[32] Li, H.W., Yu, C., Jiang, J., et al. (2016) An Anti-HER2 Anti-body Conjugated with Monomethyl Auristatin E Is Highly Effective in HER2-Positive Human Gastric Cancer. Cancer Biology & Therapy, 17, 346-354. [Google Scholar] [CrossRef] [PubMed]
[33] Wang, J.Y., Liu, Y.J., Zhang, Q.Y., et al. (2021) RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive and HER2-Low Expressing Advanced or Metastatic Breast Cancer: A Pooled Analysis of Two Studies. Journal of Clinical Oncology, 39, Article No. 1022. [Google Scholar] [CrossRef] 
[34] Zhang, J., Ji, D.M., Shen, W.A., et al. (2022) Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research, 28, 4212-4221. [Google Scholar] [CrossRef] 
[35] Cortés, J., Kim, S.B., Chung, W.P., et al. (2022) Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 386, 1143-1154. [Google Scholar] [CrossRef] 
[36] Bardia, A., Hurvitz, S.A., Rugo, H.S., et al. (2021) A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer. Future Oncology, 17, 3911-3924. [Google Scholar] [CrossRef] [PubMed]
[37] Kolberg, H.C., Andre, F., Hamilton, E., et al. (2022) Trastuzumab Deruxtecan (T-DXd) Combinations in Patients with HER2-Positive Advanced or Metastatic Breast Cancer: A Phase 1b/2, Open-Label, Multicenter, Dose-Finding and Dose-Expansion Study (DESTINY-Breast07). Oncology Research and Treatment, 45, 32-32.

为你推荐